Mundipharma Receives EU Approval for Pelmeg (Pegfilgrastim- Biosimilar)

Share this

Mundipharma Receives EU Approval for Pelmeg (Pegfilgrastim- Biosimilar)


  • Pelmeg (Pegfilgrastim- Biosimilar) is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic CT for malignancy
  • CHMP recommends Pelmeg based on the results from pharmacodynamics- pharmacokinetics- and immunogenicity comparisons with Neulasta
  • Pelmeg is Granulocyte-colony stimulating factor (G-CSF) biosimilar that stimulates bone marrow to produce more neutrophils riginally developed by Cinfa Biotech

/ article | Ref: Mundipharma | Image: Wikimedia Commons

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions